Kexing Biopharm (Stock Code: 688136) is a leading Internationalization biopharmaceutical company specializing in the research, manufacture, and commercialization of innovative medicines combining recombinant proteins, antibodies, and targeted delivery therapies, etc. Harnessing proprietary technology platforms, Kexing pioneers novel targeted biological therapies and advanced drug delivery systems to address critical unmet needs in oncology, autoimmune and infectious diseases, making transformative impact on patients. Driven by a dual strategic focus on breakthrough innovation and global outreach, Kexing is committed to becoming a world-class leader in bringing high-quality pharmaceutical solutions to patients worldwide.

Our company mainly deals in products related to oncology, immunology, ophthalmology, pulmonology, and metabolism etc… Paclitaxel for Injection ( Albumin-bound ) / Bevacizumab Injection / Eribulin Mesylate Injection / Sorafenib Tosylate Tablets / Palbociclib Capsules / Olaparib Tablets / Aflibercept Intravitreous Injection / Liraglutide Injection / Human Erythropoietin Injection / Infliximab for Injection / Adalimumab Solution for Injection / Nintedanib Esilate Soft Capsules etc…